Journal
NEUROPSYCHOPHARMACOLOGY
Volume 35, Issue 12, Pages 2339-2345Publisher
SPRINGERNATURE
DOI: 10.1038/npp.2010.103
Keywords
fMRI; smoking; smoking emotional stroop; interference; interoception; memory
Categories
Funding
- ANT North America Inc.
- AstraZeneca
- Pfizer
- Abbott Laboratories
- Alkermes
- Aspect Medical Systems
- BioResearch
- BrainCells, Inc.
- Bristol-Myers Squibb Company
- Cephalon
- Clinical Trial Solutions
- LLC
- Eli Lilly Company
- Forest Pharmaceuticals Inc.
- Ganeden
- GlaxoSmithKline
- J & J Pharmaceuticals
- Lichtwer Pharma GmbH
- Lorex Pharmaceuticals
- NARSAD
- NCCAM
- NIDA
- NIMH
- Novartis
- Organon Inc.
- Organon Inc., PamLab
- Pfizer Inc.
- Pharmavite
- Roche
- Sanofi-Aventis
- Shire
- Solvay Pharmaceuticals, Inc.
- Synthelabo
- Wyeth-Ayerst Laboratories
- GSK
- Organon
- Varian Inc.
Ask authors/readers for more resources
Attentional bias for drug-related stimuli, as measured by emotional Stroop (ES) tasks, is predictive of treatment outcomes for tobacco smoking and other abused drugs. Characterizing relationships between smoking-related attentional bias and brain reactivity to smoking images may help in identifying neural substrates critical to relapse vulnerability. To this end, we investigated putative relationships between interference effects in an offline smoking ES task and functional MRI (fMRI) measures of brain reactivity to smoking vs neutral images in women smokers. Positive correlations were found between attentional bias and reactivity to smoking images in brain areas involved in emotion, memory, interoception, and visual processing, including the amygdala, hippocampus, parahippocampal gyrus, insula, and occipital cortex. These findings suggest that smokers with elevated attentional biases to smoking-related stimuli may more readily shift attention away from other external stimuli and toward smoking stimuli-induced internal states and emotional memories. Such attentional shifts may contribute to increased interference by smoking cues, possibly increasing relapse vulnerability. Treatments capable of inhibiting shifts to drug cue-induced memories and internal states may lead to personalized tobacco dependence treatment for smokers with high attentional bias to smoking-related stimuli. Neuropsychopharmacology (2010) 35, 2339-2345; doi: 10.1038/npp.2010.103; published online 11 August 2010
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available